Last reviewed · How we verify
Extended Phase Dose Group — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Extended Phase Dose Group (Extended Phase Dose Group) — Chengdu Zenitar Biomedical Technology Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Extended Phase Dose Group TARGET | Extended Phase Dose Group | Chengdu Zenitar Biomedical Technology Co., Ltd | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Extended Phase Dose Group CI watch — RSS
- Extended Phase Dose Group CI watch — Atom
- Extended Phase Dose Group CI watch — JSON
- Extended Phase Dose Group alone — RSS
Cite this brief
Drug Landscape (2026). Extended Phase Dose Group — Competitive Intelligence Brief. https://druglandscape.com/ci/extended-phase-dose-group. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab